BASEL, Switzerland, Feb. 26 /PRNewswire-FirstCall/ -- Syngenta announced today that the Board of Directors will propose to shareholders at the Annual General Meeting on April 21, 2009, to name Stefan Borgas as a new member of the Syngenta Board.
Stefan Borgas (45) is Chief Executive Officer of Lonza, one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries, headquartered in Basel. Prior to joining Lonza in 2004 he worked in various senior international functions for BASF. Stefan Borgas holds a degree in business administration from the University of Saarbruecken, Germany, and an MBA from the University of St. Gallen, Switzerland.
Syngenta is one of the world's leading companies with more than 24,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.
Media contact: Analyst/Investor contacts:
Medard Schoenmaeckers Jennifer Gough
Switzerland +41 61 323 2323 Switzerland +41 61 323 5059
USA +1 202 737 6521
John Hudson
Switzerland +41 61 323 6793
USA +1 202 737 6520
Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefore.
